Monte Rosa TherapeuticsGLUE
Recorded

Monte Rosa Therapeutics Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration24 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Faisal KhurshidSenior Biotech Analyst

All right. Good morning, everyone. Good morning, everyone. Thank you for joining. My name is Faisal Khurshid. I am one of the Senior Biotech Analysts here at Jefferies. We are here in nice, rainy London at the Jefferies Global Healthcare Conference. Really pleased to have this morning management team at Monte Rosa Therapeutics. That is GLUE, I love your stock ticker. Markus Warmuth is on stage with me. Markus, can I ask you to kick it off, give us some opening remarks?

Markus WarmuthCEO

Yeah. First of all, thanks for having us here at this conference. Always excited to be here in London. Just a few words on Monte Rosa Therapeutics. For those who are not familiar, we are doing targeted protein degradation. We are doing it in a very special way, a modality that we like to call molecular glue degraders. These are small molecules. They are true small molecules. They bind to what is called a ubiquitin ligase that is part of the cell intrinsic protein degradation pathway. They bind to these ubiquitin ligases and essentially reshape their surface to create now a novel protein-protein interaction surface. This is a way to get rid of proteins in a very, very selective way. This has been a constant theme throughout our portfolio, exquisite selectivity, and obviously, that creates really safe molecules.

Markus WarmuthCEO

We are applying this across multiple disease areas, and I am pretty sure we are talking a lot about the existing public portfolio.

Faisal KhurshidSenior Biotech Analyst

Got it. Let us start with your NEK7 degrader, MRT-8102. Can you maybe just, let us start with sort of the concept and idea of NEK7 and where it can go, because there are a few different areas across the indications that you have chosen for phase II, and each have very different kind of development considerations. So, we will talk about that, but maybe just to start, what is this molecule and why does it have this breadth of applicability?

Markus WarmuthCEO

Yeah. We are now in inflammatory diseases, trying to target the NLRP3 pathway. This is an inflammasome that is mostly responsible for what we call sterile inflammation. It is not as much engaged in host defense. It is really more trying to deal with anything that is intrinsic metabolites, and this is essentially how we are sort of positioning the molecule, at least for now, like all sorts of inflammatory conditions, gout, ASCVD, HS, driven by either crystals of metabolites or oxidized versions of metabolites. I have mentioned some of the indications. We have prioritized, obviously, ASCVD really remains a focus for us, despite, as some of you know, some of the challenges post-Novo failure around the IL-6 antibody. The first phase II, though, that is now initiating is in gout, and again, very good validation for that indication around the NLRP3 pathway.

Faisal KhurshidSenior Biotech Analyst

Got it. Across your three indications that you have chosen for phase II, you have ASCVD, you have gout, you have HS. Can you talk to us about how you see the risk profile across the three? If I were to ask you to force rank them from highest probability of success to least, how do you think about that?

Markus WarmuthCEO

Yeah, I mean, it is a great question. It is a little bit like asking me who my favorite child is.

Markus WarmuthCEO

Yeah. Also, that is- Sorry an easier answer because I only have two and not three.

Markus WarmuthCEO

That makes it easy. But honestly, I mean, we like all indications, right?

Markus WarmuthCEO

I mean, let's go back to why we picked them. Very strong validation, clinical and preclinical validation for the NLRP3 inflammasome driving at least inflammation and pain in these diseases. We spent a lot of time looking at publicly available data sets for what's the level of pathway activation, NLRP3 pathway activation. Between that and existing proof of concepts, gout, ASCVD, and HS rose to the top. You could argue that gout at this point maybe has the least risk. Gout in general as an indication does fly a little bit under the radar, so some of that data isn't as well known as, for example, ZEUS' failure. There are now novel IL-1β antibodies out of China, just recently added to the proof of concept for the pathway in gout.

Markus WarmuthCEO

And so, all things considered, and also looking at sort of the size and the ease of conducting that phase II trial, maybe the lowest risk, but you never know until you know. We really still are very confident around ASCVD. I've referenced that infamous, now infamous ZEUS trial quite a bit by now. This was Novo's attempt to improve outcome, cardiovascular outcome in ASCVD using an IL-6 antibody. Didn't go so well. I think we now do understand why the trial failed. It is really a combination of IL-6 not being a good target, probably their antibody not being the best antibody to neutralize IL-6, because we now know after they've published the data that the antibody left around 20%-25% IL-6 on the table. So, it's not a complete inhibition of the pathway, although their CRP decreases in a way suggested it would be.

Markus WarmuthCEO

There's clearly too much IL-6 left in the system, and there were clearly also flaws in the trial design, meaning too many comorbidities that likely influenced how modifiable the cardiovascular risk of those patients was. We do think all of this can be addressed in our program. We're going to go after the pathway fairly upstream, and certainly the trial design eventually will look very different from what Novo did.

Faisal KhurshidSenior Biotech Analyst

Got it. I want to talk about gout, because you mentioned you're starting the GEMINI-1 study, I believe shortly here. Can you talk about the trial design? I believe you said that you will be able to show some initial data next year. What should we be looking for in that dataset?

Markus WarmuthCEO

Yeah, so, this is a fairly simple trial design. GEMINI-1, we're actually looking at prevention of gout flares after managing an acute flare. So this will be patients that we like to call frequent flare-ers. So they do have a couple of flares per year, if not more. They will go on the trial as they have the first flare. So, we'll start therapy at that point, and then obviously the important readout will be after that first flare on the trial has been managed, can we prevent additional flares? Because that's really what's important in gout, right? I think there's a lot of talk now about urate-lowering drugs. They only help so and so much, and quite honestly, patients care only so and so much because they do not care about their urate levels.

Markus WarmuthCEO

They care about, "Do I have another very painful flare or not?" So we do think that at the end of the day, flare prevention, if that works out, is the better market. So it's a relatively small trial, two dose levels, open-label expansion. We often get the question around placebo control. We really do think placebo controls are important. In this case, though, it doesn't make sense, because I would either have to tell a patient that they have to suck up the pain for 72 hours or more, or offer them rescue medicine, which is of course what you do, and then when you offer rescue medicine, obviously it's not really a true placebo control anymore. That said, I referenced the IL-1β antibodies that have emerged recently in China.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day